Volkmar Henschel

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.2K citations · Full text

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology · 2019 · 1.2K citations

Breast Oncology, Oncology, Medicine +7

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 636 citations · Full text

Non-small-cell Lung Cancer, Medicine, Pathology +7

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology · 2021 · 437 citations · Full text

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

David Cameron, Julia Brown, Rebecca Dent et al. · The Lancet Oncology · 2013 · 432 citations

Adjuvant Bevacizumab-containing Therapy, Breast Oncology, Medicine +7